An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

Trial Profile

An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms REGARD
  • Sponsors Bayer
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 3 Jul 2017 to 31 Aug 2017.
    • 07 Jun 2017 Planned End Date changed from 16 Jun 2017 to 3 Jul 2017.
    • 23 May 2017 Planned End Date changed from 1 Mar 2017 to 16 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top